long half-life and large variability [Regulatives / Guidelines]

posted by martin  – Austria, 2020-07-29 22:49 (662 d 21:10 ago) – Posting: # 21801
Views: 2,060

dear ElMaestro,

Thank you for your swift reply and sharing your thoughts.

There are two types of covariates (type 1: continous = subject specfic values; and type 2: categorical variable with a few levels).

At the first glance a different regulatory pathway might be worth considering based on a PK or exposure similarity evalulation as in such a case there could be more flexibility regarding acceptance of statistical models used to test for equivalence in PK metrics.

Happy to get your thoughts on this idea.

best regards


Complete thread:

UA Flag
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 17 (0 registered, 17 guests [including 9 identified bots]).
Forum time: Monday 19:59 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz